Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study
|ClinicalTrials.gov Identifier: NCT00717002|
Recruitment Status : Completed
First Posted : July 16, 2008
Last Update Posted : December 11, 2013
The overall objective of the study is to assess the feasibility of the use of blood for the detection of EGFR mutations in patients with non-small cell lung cancer (NSCLC)
Specific aims are:
- To assess the use of immuno-separation techniques to enrich the tumor cell population in the blood of NSCLC patients.
- To assess the use of denaturing high performance liquid chromatography (DHPLC) assay for the detection of EGFR mutations in the blood of NSCLC patients.
|Condition or disease|
|Non Small Cell Lung Cancer|
|Study Type :||Observational|
|Official Title:||Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study|
|Study Start Date :||February 2008|
|Primary Completion Date :||April 2013|
|Study Completion Date :||April 2013|
Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00717002
|National University Hospital|
|Principal Investigator:||Ross Andrew Soo, MRCP, MB ChB||National University Hospital, Singapore|